Literature DB >> 7682073

Cloning and functional analysis of the mouse c-kit promoter.

H Yasuda1, S J Galli, E N Geissler.   

Abstract

The c-kit protooncogene encodes a tyrosine kinase receptor expressed during ontogeny and adult life by several important and developmentally distinct cell lineages. Mice carrying germ line c-kit mutations exhibit deficiencies in most of these lineages, demonstrating that c-kit function is necessary for their normal development. To facilitate the identification of cis-acting elements which regulate tissue-specific c-kit expression, we cloned and characterized a mouse c-kit promoter which is functional in different cell types. A major c-kit transcription initiation site (TIS), located 58 bp upstream from the translation initiation codon, is utilized in mouse mast cells and in c-kit-positive cells in the mouse cerebellum. The effects of deletions in the 5' flanking region on reporter gene activity identify three short regulatory regions which function in both mouse and human c-kit positive cell lines. The nucleotide sequence of this region does not include CCAAT or TATA boxes but contains consensus binding sites for Sp1, Ap-2 and several short GA-rich elements which resemble binding sites for the ETS-domain proteins.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7682073     DOI: 10.1006/bbrc.1993.1301

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  The potent enhancer activity of the polycythemic strain of spleen focus-forming virus in hematopoietic cells is governed by a binding site for Sp1 in the upstream control region and by a unique enhancer core motif, creating an exclusive target for PEBP/CBF.

Authors:  C Baum; K Itoh; J Meyer; C Laker; Y Ito; W Ostertag
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

2.  Transgenic mice with overexpression of mutated human optineurin(E50K) in the retina.

Authors:  Qingfeng Meng; Zheng Xiao; Huiping Yuan; Fei Xue; Yuanmao Zhu; Xinrong Zhou; Binbin Yang; Jingbo Sun; Bo Meng; Xian Sun; Fang Cheng
Journal:  Mol Biol Rep       Date:  2011-06-17       Impact factor: 2.316

3.  A novel anti-c-Kit antibody-drug conjugate to treat wild-type and activating-mutant c-Kit-positive tumors.

Authors:  Jin-Ock Kim; Kwang-Hyeok Kim; Eun Ji Baek; Bomi Park; Min Kyung So; Byoung Joon Ko; Han-Jik Ko; Sang Gyu Park
Journal:  Mol Oncol       Date:  2021-08-29       Impact factor: 6.603

4.  c-kit expression identifies cardiovascular precursors in the neonatal heart.

Authors:  Yvonne N Tallini; Kai Su Greene; Michael Craven; Alyson Spealman; Martin Breitbach; James Smith; Patricia J Fisher; Michele Steffey; Michael Hesse; Robert M Doran; Ashley Woods; Babu Singh; Andrew Yen; Bernd K Fleischmann; Michael I Kotlikoff
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-04       Impact factor: 11.205

5.  A conserved quadruplex motif located in a transcription activation site of the human c-kit oncogene.

Authors:  Himesh Fernando; Anthony P Reszka; Julian Huppert; Sylvain Ladame; Sarah Rankin; Ashok R Venkitaraman; Stephen Neidle; Shankar Balasubramanian
Journal:  Biochemistry       Date:  2006-06-27       Impact factor: 3.162

6.  Targeting gene expression to haemopoietic stem cells: a chromatin-dependent upstream element mediates cell type-specific expression of the stem cell antigen CD34.

Authors:  G May; T Enver
Journal:  EMBO J       Date:  1995-02-01       Impact factor: 11.598

7.  Pim1 kinase regulates c-Kit gene translation.

Authors:  Ningfei An; Bo Cen; Houjian Cai; Jin H Song; Andrew Kraft; Yubin Kang
Journal:  Exp Hematol Oncol       Date:  2016-12-30

8.  Characterization of the promoter region of the human c-kit proto-oncogene.

Authors:  K Yamamoto; A Tojo; N Aoki; M Shibuya
Journal:  Jpn J Cancer Res       Date:  1993-11

Review 9.  Recent Progress of Targeted G-Quadruplex-Preferred Ligands Toward Cancer Therapy.

Authors:  Sefan Asamitsu; Shunsuke Obata; Zutao Yu; Toshikazu Bando; Hiroshi Sugiyama
Journal:  Molecules       Date:  2019-01-24       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.